Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease

Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson’s disease

Live webcast scheduled for Monday, December 11 from 10:00 to 11:30 a.m. ET

CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a tavapadon investor webcast on Monday, December 11, from 10:00 to 11:30 a.m. ET.

Cerevel will lead an in-depth discussion of tavapadon, its D1/D5 partial agonist currently in Phase 3 development for the treatment of Parkinson’s disease. The event will include remarks and insights from Hubert Fernandez, M.D., Director, Center for Neurological Restoration at Cleveland Clinic and recognized key opinion leader in Parkinson’s disease.

“I am excited about the potential of tavapadon, the first and only selective D1/D5 partial agonist being studied for Parkinson’s disease,” said Dr. Raymond Sanchez, Cerevel’s chief medical officer. “We know there is a significant need for a novel treatment option that provides sustained motor control without non-motor side effect tradeoffs and look forward to discussing our hope for delivering tavapadon to people living with Parkinson’s."

Tavapadon is currently being studied for Parkinson’s disease in the Phase 3 TEMPO program. The TEMPO-3 trial, which is expected to read out in the first half of 2024, is evaluating tavapadon as an adjunctive treatment to levodopa. The TEMPO-1 and TEMPO-2 trials, which will read out in the second half of 2024, are evaluating tavapadon as a monotherapy treatment.

This investor event will provide a detailed look at tavapadon’s differentiating features, previously published clinical data, the design of the TEMPO program, and the potential opportunity of tavapadon to meet unmet patient needs within the Parkinson’s disease treatment paradigm. The presentations will be followed by time for questions.

The live webcast, along with supporting slides, will be accessible on the investors section of Cerevel’s website here. Following the live webcast, an archived version of the event will be available on the website.

About Cerevel Therapeutics
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases by combining its deep expertise in neurocircuitry with a focus on targeted receptor subtype selectivity and a differentiated approach to pharmacology. Cerevel Therapeutics has a diversified pipeline comprised of five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder, and Parkinson’s disease. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or potential acquisitions. For more information, visit www.cerevel.com.